ES2114588T3 - Forma farmaceutica de un gel acuoso que contiene un retinoide. - Google Patents

Forma farmaceutica de un gel acuoso que contiene un retinoide.

Info

Publication number
ES2114588T3
ES2114588T3 ES93302926T ES93302926T ES2114588T3 ES 2114588 T3 ES2114588 T3 ES 2114588T3 ES 93302926 T ES93302926 T ES 93302926T ES 93302926 T ES93302926 T ES 93302926T ES 2114588 T3 ES2114588 T3 ES 2114588T3
Authority
ES
Spain
Prior art keywords
aqueous gel
retinoid
gel containing
pharmaceutical form
retinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93302926T
Other languages
English (en)
Inventor
Richard K Farng
Shirley M Ng
Gerard J Gendimenico
Stanley B Wrobel Jr
James A Mezick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Application granted granted Critical
Publication of ES2114588T3 publication Critical patent/ES2114588T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS RETINOIDES DE GEL ACUOSO Y SUS METODOS DE USO. MAS ESPECIFICAMENTE, LOS COMPUESTOS RETINOIDES DE GEL ACUOSO DE LA INVENCION UTILIZAN PARTICULAS MICRONIZADAS DE RETINOIDES, PARTICULARMENTE TRETINOINA, PARA PROPORCIONAR UN GEL ACUOSO DE APLICACION TOPICA DE TALES RETINOIDES A LA PIEL, LO QUE REDUCE AL MINIMO LA IRRITACION DE LA PIEL CONSERVANDO EN CAMBIO LA EFICACIA DEL MEDICAMENTO.
ES93302926T 1992-04-16 1993-04-15 Forma farmaceutica de un gel acuoso que contiene un retinoide. Expired - Lifetime ES2114588T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86968492A 1992-04-16 1992-04-16

Publications (1)

Publication Number Publication Date
ES2114588T3 true ES2114588T3 (es) 1998-06-01

Family

ID=25354073

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93302926T Expired - Lifetime ES2114588T3 (es) 1992-04-16 1993-04-15 Forma farmaceutica de un gel acuoso que contiene un retinoide.

Country Status (21)

Country Link
US (1) US5643584A (es)
EP (1) EP0566405B1 (es)
JP (1) JP2779303B2 (es)
KR (1) KR970007901B1 (es)
AT (1) ATE163540T1 (es)
AU (1) AU670777B2 (es)
CA (1) CA2094084C (es)
DE (1) DE69317139T2 (es)
DK (1) DK0566405T3 (es)
ES (1) ES2114588T3 (es)
FI (1) FI931717L (es)
GR (1) GR3026597T3 (es)
HU (1) HUT64468A (es)
IL (1) IL105413A (es)
MX (1) MX9302244A (es)
MY (1) MY111791A (es)
NO (1) NO303816B1 (es)
NZ (1) NZ247387A (es)
SG (1) SG52276A1 (es)
TW (1) TW429152B (es)
ZA (1) ZA932653B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029804T2 (de) * 1989-06-07 1997-09-04 Gail S Bazzano VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
AU688757B2 (en) * 1993-05-27 1998-03-19 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US5646186A (en) * 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
FR2718021B1 (fr) * 1994-04-05 1996-06-28 Fabre Pierre Cosmetique Composition topique à base de rétinal.
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
JP3940209B2 (ja) 1996-11-14 2007-07-04 株式会社資生堂 可溶化化粧料
US6008254A (en) 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
SE9801647D0 (sv) * 1998-05-12 1998-05-12 Interhealth Ab Therapeutic composition
FR2781371B1 (fr) 1998-07-21 2001-04-27 Oreal Composition cosmetique aqueuse transparente a une seule phase
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
CN1328443A (zh) * 1998-11-23 2001-12-26 宝洁公司 皮肤除臭和卫生消毒组合物
US6656456B2 (en) * 1998-11-23 2003-12-02 The Procter & Gamble Company Skin deodorizing compositions
US6262117B1 (en) * 1999-02-18 2001-07-17 Allergan Sales, Inc. Method and composition for treating acne
US6114348A (en) * 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
FR2807662A1 (fr) * 2000-04-12 2001-10-19 Cll Pharma Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications
AU5378201A (en) * 2000-04-26 2001-11-07 Watson Pharmaceuticals Inc Minimizing adverse experience associated with oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20040087520A1 (en) * 2002-10-25 2004-05-06 Chowdhury Dipak K. Compositions and methods for delivery of therapeutic agents
CA2505407A1 (en) * 2002-12-12 2004-06-24 Galderma Research & Development, S.N.C. Aqueous-alcoholic depigmenting gel containing a phenolic derivative and a retinoid
US20070099996A1 (en) * 2003-05-20 2007-05-03 Shashikanth Isloor Pharmaceutical compositions of acitretin
WO2005048929A2 (en) * 2003-11-13 2005-06-02 Galileo Pharmaceuticals, Inc. Plant-derived protein extract compositions and methods
JP2007536259A (ja) * 2004-05-06 2007-12-13 イヴレア ファーマスーティカルズ インコーポレイテッド 活性薬剤の送達のための粒子
US20060141046A1 (en) * 2004-05-06 2006-06-29 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US7662855B2 (en) 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
WO2006065991A2 (en) * 2004-12-17 2006-06-22 Dr. Reddy's Laboratories Ltd. Dispersion for delivering active agents
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
FR2879459B1 (fr) * 2004-12-22 2007-02-16 Galderma Res & Dev Composition comprenant de l'adapalene solubilise avec des cyclodextrines
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US7803357B2 (en) * 2006-10-30 2010-09-28 John V Cappello Topical and transdermal treatments using urea formulation
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
CN101903022A (zh) * 2007-10-18 2010-12-01 梅迪奇斯医药公司 类维生素a和过氧化苯甲酰水凝胶
US20100029765A1 (en) * 2008-07-30 2010-02-04 Ranbaxy Labortories Limited Topical aqueous composition comprising tretinoin
EP2432453A2 (en) 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Topical retinoid solutions
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
PL2544532T3 (pl) 2010-03-12 2017-08-31 Monsanto Technology Llc Agrochemiczne kompozycje żelowe
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
CN110055320A (zh) 2012-03-17 2019-07-26 加州大学评议会 痤疮的快速诊断和个体化治疗
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
MX2016005645A (es) 2013-10-31 2017-01-05 Sun Pharmaceutical Ind Ltd Composicion farmaceutica topica de acitretina.
JP6602034B2 (ja) 2014-04-02 2019-11-06 日東電工株式会社 標的化分子およびその使用
CA2943733C (en) 2014-04-07 2022-03-01 Nitto Denko Corporation Polymer-based hydrotropes for hydrophobic drug delivery
CN105434409A (zh) * 2014-09-24 2016-03-30 富泰尔斯有限责任公司 组合物、组合物的用途及制造方法
EP3108875A1 (en) * 2015-06-23 2016-12-28 Galderma Research & Development Compositions comprising water dispersible nanoparticles of a retinoid compound
CN118121574A (zh) * 2022-12-02 2024-06-04 南京毓浠医药技术有限公司 一种含维a酸组合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) * 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US3906108A (en) * 1973-10-12 1975-09-16 Johnson & Johnson Stabilized tretinoin cream emulsion
IN142640B (es) * 1975-01-17 1977-08-06 Johnson & Johnson
US4247547A (en) * 1979-03-19 1981-01-27 Johnson & Johnson Tretinoin in a gel vehicle for acne treatment
DE3119383A1 (de) * 1981-05-15 1982-12-02 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US4826871A (en) * 1985-03-13 1989-05-02 Gressel Philip D Topical ophthalmic compositions containing one or more retinoids
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
MY105521A (en) * 1989-04-17 1994-10-31 Healthpoint Ltd Moisturizing vehicle for topical application of vitamin a acid.
US5476852A (en) * 1989-05-03 1995-12-19 Janssen Pharmaceutica N.V. Method of topically treating acne vulgaris, hyperkeratotic dermatoses, and photo-aging of the skin
FR2647015B1 (fr) * 1989-05-17 1994-05-06 Cird Gel aqueux a base d'acide retinoique et son utilisation en medecine humaine et en cosmetique
DE69029804T2 (de) * 1989-06-07 1997-09-04 Gail S Bazzano VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL

Also Published As

Publication number Publication date
DK0566405T3 (da) 1998-09-28
EP0566405A3 (en) 1993-12-15
JP2779303B2 (ja) 1998-07-23
FI931717A7 (fi) 1993-10-17
TW429152B (en) 2001-04-11
NO303816B1 (no) 1998-09-07
NO931390D0 (no) 1993-04-15
AU3685893A (en) 1993-10-21
EP0566405B1 (en) 1998-03-04
DE69317139D1 (de) 1998-04-09
KR970007901B1 (ko) 1997-05-17
IL105413A (en) 1999-09-22
MY111791A (en) 2001-01-31
MX9302244A (es) 1994-05-31
CA2094084A1 (en) 1993-10-17
HUT64468A (en) 1994-01-28
FI931717L (fi) 1993-10-17
ZA932653B (en) 1994-10-15
GR3026597T3 (en) 1998-07-31
CA2094084C (en) 1998-06-30
IL105413A0 (en) 1993-08-18
HU9301114D0 (en) 1993-07-28
NZ247387A (en) 1996-02-27
NO931390L (no) 1993-10-18
US5643584A (en) 1997-07-01
EP0566405A2 (en) 1993-10-20
KR930021210A (ko) 1993-11-22
AU670777B2 (en) 1996-08-01
SG52276A1 (en) 1998-09-28
ATE163540T1 (de) 1998-03-15
DE69317139T2 (de) 1998-08-20
FI931717A0 (fi) 1993-04-15
JPH06100443A (ja) 1994-04-12

Similar Documents

Publication Publication Date Title
MX9302244A (es) Composicion de gel acuoso de retinoides.
ES2079063T3 (es) Utilizacion de analogos de vitamina d en el tratamiento del acne.
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
ES2134355T3 (es) Copolimeros elastomeros termoplasticos y composiciones para el cuidado del cabello y de la piel que los contienen.
MX9400206A (es) Derivados de vinil-azaindol, proceso para su preparacion y composiciones farmaceuticas que los contienen.
ES2188586T3 (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura.
ES2185241T3 (es) Utilizacion de composiciones cosmeticas que contienen al menos una uxina.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
UY25067A1 (es) Acetato de sertralina, composiciones farmacéuticas que lo contienen y procedimientos de preparación.
AR012125A1 (es) UNA SAL DE UN COMPUESTO DERIVADO DEL ÁCIDO NAFTIRIDINA CARBOXíLICO , SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO , PROCEDIMIENTO PARA PREPARARLA Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE
AR012376A1 (es) Formulacion de gel para la aplicacion topica
GT200100199A (es) Nuevos retinoides para el tratamiento de efisema.
ES2062229T3 (es) Formulacion extrasuave de gel de ducha y de champu para los cabellos con baja concentracion de agentes tensioactivos.
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
ES2166988T3 (es) Terapia de administracion uniforme de farmacos.
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
ES2174293T3 (es) Microesferas farmaceuticas de acido valproico para la administracion oral.
CL2001002303A1 (es) Compuestos derivados de triptamina; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar desordenes cardiovasculares, del sistema nervioso central, cronobiologicos y del sistema inmune, entre otros.
AR017664A1 (es) Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2060076T3 (es) Nuevos derivados de tetralina.
ES2090671T3 (es) Composiciones para la pigmentacion de la piel o de los cabellos que contienen un extracto de marrubium vulgare.
ES2032572T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica para aplicacion topica sobre la piel.
ES2133467T3 (es) Agente endoparasitizida a base de octadepsipeptidos de cadena abierta.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 566405

Country of ref document: ES